Changes

814 bytes added , 27 February

no edit summary

Line 2: Line 2:

[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]

−

+

(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ HUGO-approved gene names and symbols] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author_Instructions]] and [[Frequently Asked Questions (FAQs)|FAQs]] as well as contact your [[Leadership|Associate Editor]] or [mailto:CCGA@cancergenomics.org Technical Support])

−

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation]].

−

~~}}</blockquote>~~

==Primary Author(s)*==

Line 14: Line 14:

==Cancer Category / Type==

−

Put your text here

+

Put your text here

==Cancer Sub-Classification / Subtype==

Line 236: Line 236:

==Links==

−

[[Fibrin-~~Associated Diffuse Large~~ B-cell ~~Lymphoma~~]]

+

[[HAEM5:Fibrin-associated large B-cell lymphoma]]

Put your links here (use "Link" icon at top of page)

DanTest

29

edits

Changes

HAEM5:Diffuse large B-cell lymphoma associated with chronic inflammation (view source)

Revision as of 10:50, 27 February 2024